SCHEMBL5772834

SCHEMBL5772834

C=C(CCc1ccccc1)N1CCCC1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 3/20 0.66
TDP1 Q9NUW8 1/20 0.66
NAAA Q02083 1/20 0.54
SMN1; SMN2 Q16637 2/20 0.50
RAB9A P51151 2/20 0.50
SLC6A3 Q01959 1/20 0.50
HTT P42858 1/20 0.50
POLB P06746 1/20 0.49
SIGMAR1 Q99720 2/20 0.48
HPGD P15428 1/20 0.48
FKBP1A P62942 1/20 0.47
GAA P10253 1/20 0.45
KEAP1 Q14145 1/20 0.45
MEN1 O00255 2/20 0.44
KMT2A Q03164 2/20 0.44
TSHR P16473 1/20 0.44
ALDH1A1 P00352 1/20 0.43
BLM P54132 1/20 0.43
PKM P14618 1/20 0.43
STAT1 P42224 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21700206 0.87 NPC1 (0.56) NPC1TDP1NAAASMN1; SMN2RAB9A
SCHEMBL3700679 0.79 NPC1 (1.00) NPC1TDP1NAAASMN1; SMN2RAB9A
SCHEMBL20630807 0.78 NPC1 (0.62) NPC1TDP1NAAASMN1; SMN2RAB9A
SCHEMBL17087869 0.78 NPC1 (0.96) NPC1TDP1NAAASMN1; SMN2RAB9A
SCHEMBL9528419 0.78 NPC1 (0.62) NPC1TDP1NAAASMN1; SMN2RAB9A
SCHEMBL6285963 0.78 NPC1 (0.96) NPC1TDP1NAAASMN1; SMN2RAB9A
SCHEMBL25432319 0.76 NPC1 (0.93) NPC1TDP1NAAASMN1; SMN2RAB9A
SCHEMBL8599293 0.73 NPC1 (0.81) NPC1TDP1NAAASMN1; SMN2RAB9A
SCHEMBL19443719 0.73 SIGMAR1 (0.59) NPC1RAB9ASIGMAR1ALDH1A1
SCHEMBL26027439 0.73 MAPT (0.60) NPC1TDP1SMN1; SMN2RAB9ASIGMAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2022256554-A1 FLUORINATED TRYPTAMINE COMPOUNDS, ANALOGUES THEREOF, AND METHODS USING SAME UNIVERSITY OF THE SCIENCES (US) 2022-12-08 WO disclosed
WO-2022167867-A1 SUBSTITUTED CYCLIC MODULATORS OF PROTEIN PHOSPHATASE 2A (PP2A) AND METHODS USING SAME RAPPTA THERAPEUTICS OY (FI) 2022-08-11 WO disclosed
WO-2020202183-A1 THE PROCESS FOR THE PREPARATION OF UPADACITINIB AND ITS INTERMEDIATES MYLAN LABORATORIES LIMITED (IN) 2020-10-08 WO disclosed
EP-1054887-B1 BICYCLIC PYRIDINE AND PYRIMIDINE DERIVATIVES AS NEUROPEPTIDE Y RECEPTOR ANTAGONISTS AMGEN INC (US) 2006-04-12 EP disclosed
US-6583154-B1 Neuropeptide Y antagonist; pyrrolo-(3,2-b)pyridines and pyrrolo-(3,2-d)pyrimidines AMGEN INC. 2003-06-24 US disclosed
US-6187777-B1 PYRROLO(3,2-D)PYRIMIDINE DERIVATIVES; NEUROPEPTIDE Y AND CORTICOTROPIN RELEASING FACTOR MODULATORS; DIETETICS; ANTIDIABETIC, ANTIINFLAMMATORY, AND ANTITUMOR AGENTS AMGEN INC. 2001-02-13 US disclosed
EP-1054887-A1 BICYCLIC PYRIDINE AND PYRIMIDINE DERIVATIVES AS NEUROPEPTIDE Y RECEPTOR ANTAGONISTS Amgen Inc. (US) 2000-11-29 EP disclosed
WO-1999040091-A1 BICYCLIC PYRIDINE AND PYRIMIDINE DERIVATIVES AS NEUROPEPTIDE Y RECEPTOR ANTAGONISTS AMGEN INC. (US) 1999-08-12 WO disclosed